Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fosifloxuridine Nafalbenamide · NUC-3373, CPF-373

Small molecule · Inhibitor of Thymidylate synthase (TYMS)

Phase 1/2 Most advanced trial (none active)
2 Registered trials

What is Fosifloxuridine Nafalbenamide?

Fosifloxuridine nafalbenamide is a phosphoramidate prodrug of the monophosphate form of 5-fluoro-2'-deoxyuridine, which is taken up by tumor cells and converted to FUDR-MP. FUDR-MP inhibits thymidylate synthase, depleting thymidine triphosphate and DNA synthesis. It is studied in colorectal cancer and other solid tumors and melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NUC-3373, CPF-373, NUC-3073, Nucleotide analogue
Drug type
Small molecule
Targets
Thymidylate synthase (TYMS)
Mechanism
Inhibitor of Thymidylate synthase (TYMS)
Pathways
DNA synthesis, thymidine triphosphate depletion
Therapy area
Oncology
In trials of
NCNA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
4YO6QT3SZ9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05714553 Phase 1/2 Advanced Cancer Terminated NCNA
NCT03428958 Phase 1/2 Colorectal Cancer Completed NCNA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerAdvanced Solid TumorClassical Hodgkin LymphomaColorectal CancerColorectal CarcinomaColorectal NeoplasmsColorectal TumorsHead and Neck Squamous Cell CarcinomaMelanomaMetastatic CancerNeoplasm MalignantNeoplasms, ColorectalNon Small Cell Lung CancerRenal Cell Carcinoma

Other drugs acting on TYMS

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.